Trial Profile
Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutations. Randomised phase II study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Cisplatin; Doxorubicin; Methotrexate; Vinblastine
- Indications Urogenital cancer
- Focus Therapeutic Use
- 04 Mar 2021 Status changed from active, no longer recruiting to completed.
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 03 Apr 2012 Actual initiation date (26 Feb 2010) added as reported by European Clinical Trials Database.